These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9218083)

  • 1. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.
    Houghton LA; Rogers J; Whorwell PJ; Campbell FC; Williams NS; Goka J
    Aliment Pharmacol Ther; 1997 Jun; 11(3):561-8. PubMed ID: 9218083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists.
    Wallis RM
    Life Sci; 1995; 56(11-12):861-8. PubMed ID: 10188786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computerized planimetry in the objective assessment of the antispasmodic effect of Zamifenacin in double contrast barium enemas.
    Hughes T; Wright AR; Owen JP; Keir MJ
    Br J Radiol; 1996 Apr; 69(820):301-5. PubMed ID: 8665128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral cisapride on small bowel motility in irritable bowel syndrome.
    Evans PR; Bak YT; Kellow JE
    Aliment Pharmacol Ther; 1997 Oct; 11(5):837-44. PubMed ID: 9354190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
    Scarpignato C; Pelosini I
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
    Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
    Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
    Houghton LA; Foster JM; Whorwell PJ
    Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the treatment of irritable bowel syndrome.
    De Schryver AM; Samsom M
    Scand J Gastroenterol Suppl; 2000; (232):38-42. PubMed ID: 11232489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of colonic motility by intravenous nicardipine in irritable bowel syndrome.
    Prior A; Harris SR; Whorwell PJ
    Gut; 1987 Dec; 28(12):1609-12. PubMed ID: 3428688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.
    Houghton LA; Jackson NA; Whorwell PJ; Cooper SM
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
    Maxton DG; Morris J; Whorwell PJ
    Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the interaction of zamifenacin at muscarinic receptors in vitro.
    Watson N; Reddy H; Stefanich E; Eglen RM
    Eur J Pharmacol; 1995 Oct; 285(2):135-42. PubMed ID: 8566131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics.
    Sullivan MA; Cohen S; Snape WJ
    N Engl J Med; 1978 Apr; 298(16):878-83. PubMed ID: 345122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome.
    Lanfranchi GA; Bazzocchi G; Campieri M; Brignola C; Fois F; Imbimbo BP
    Eur J Clin Pharmacol; 1988; 33(6):571-5. PubMed ID: 3366160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome.
    Niederau C; Faber S; Karaus M
    Gastroenterology; 1992 Jun; 102(6):1889-98. PubMed ID: 1587408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.
    Noor N; Small PK; Loudon MA; Hau C; Campbell FC
    Scand J Gastroenterol; 1998 Jun; 33(6):605-11. PubMed ID: 9669632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.